No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
AU Stock MarketDetailed Quotes
VBLD Vanguard Global Infrastructure ETF
- 64.850
- +0.410+0.64%
20min DelayNot Open Jul 22 15:47 AET
64.850High64.500Low
64.850High64.500Low6.15KVolume64.500Open64.440Pre Close398.30KTurnover66.55452wk High0.11%Turnover Ratio5.51MShares55.63352wk Low--EPS TTM357.57MFloat Cap66.554Historical High--P/E (Static)5.51MShs Float41.952Historical Low--EPS LYR0.54%Amplitude1.77Dividend TTM--P/B1Lot Size2.73%Div YieldTTM
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Behind the Scenes of NextEra Energy's Latest Options Trends
Investors with a lot of money to spend have taken a bullish stance on NextEra Energy (NYSE:NEE).And retail traders should know.We noticed this today when the trades showed up on publicly available
Here's How Much You Would Have Made Owning American Tower Stock In The Last 20 Years
American Tower (NYSE:AMT) has outperformed the market over the past 20 years by 5.92% on an annualized basis producing an average annual return of 14.32%. Currently, American Tower has a market
BMO Capital Maintains Outperform on NextEra Energy Partners, Lowers Price Target to $28
BMO Capital analyst James Thalacker maintains NextEra Energy Partners (NYSE:NEP) with a Outperform and lowers the price target from $32 to $28.
NextEra Energy Partners Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 2.79% BMO Capital $32 → $28 Maintains Outperform 07/09/2024 — Raymond James Downgrades
Financials Dominate in Q2 as Wall Street Slides Amidst Concerns on Tech - Earnings Scorecard
Real Estate Stocks Gain as Traders Look for Alternatives to Tech Stocks
Comments
The trial of VB-601 may add value but hiring an advisor for strategic options and reporting losses indicate resource pressure and strategy shift, thus casting doubt on future performance.
Press Release: VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateMatthew Trudeau's appointment as CCO massively benefits VBL, given his extensive experience in leading commercial practices at different biotech firms. His expertise is expected to be crucial in preparing for the anticipated OVAL Phase 3 trial readout in the second half of 2022.
EIC Accelerator funds VBL as it approaches the final enrollment phase of its key product candidate, ofra-vec (VB-111), for ovarian cancer. The CEO perceives this investment as acknowledgment of the potential ofra-vec offers to patients and the current critical need in ovarian cancer therapies.
Read more